The National Cancer Institute has once again recognized the UC Davis Comprehensive Cancer Center as one of the nation’s most prestigious cancer centers, awarding it $ 17.5 million over five years and renewing the “global” designation. from the cancer center. The designation is in recognition of the breadth and depth of the cancer center in cancer research, clinical care, cancer control and population science.
The NCI has once again recognized the UC Davis Comprehensive Cancer Center as one of the best cancer centers in the country.
NCI’s renewed grant will support the cancer center’s innovative research, world-class patient care, education, and community outreach and engagement programs. Treatment at NCI-designated cancer centers is associated with better outcomes for many people with cancer and we are honored to receive this important vote of confidence from NCI. “
Gary May, Chancellor of UC Davis
The UC Davis Comprehensive Cancer Center is one of 51 centers to receive full designation nationwide. The peer review process for the NCI designation is among the most rigorous in the country, requiring evidence of collaboration and leadership as well as the demonstration of high quality programs in research, clinical care, education and community outreach.
“On behalf of patients in the region, UC Davis Health is grateful and honored that the National Cancer Institute has awarded the prestigious ‘global’ ranking to our cancer center and its efforts to reduce cancer in the region,” said David Lubarsky, CEO of UC Davis Health. . “We are a cornerstone in the region’s fight against cancer and this award signifies that we meet the highest standards of excellence in oncology research, diagnosis and treatment. We look forward to serving and coordinating cancer care in Northern California for years to come. “
Outside of San Francisco, the UC Davis Comprehensive Cancer Center is the only NCI-designated bay area center north of Portland and east of Salt Lake City, with more than 100,000 patients visiting each. year.
The greater region has a very diverse population with a considerable cancer burden in Northern California and the Central Valley. Part of the funding will be directed to programs designed to address cancer-related disparities. These ongoing programs aim to reduce the burden of cancer in underserved communities that have for too long carried a greater burden.
A new series of education, training and career development initiatives will expand the diversity of UC Davis scientists pursuing careers in cancer research and clinical care.
Primo “Lucky” Lara Jr. is director of the UC Davis Comprehensive Cancer Center and led the NCI’s grant renewal process.
“The rapid pace of discovery and improved cancer treatments at NCI-designated cancer centers like ours are increasing cancer survival and improving the quality of life for patients in our region,” said Primo “Lucky Lara Jr., UC Davis Comprehensive Cancer Center director, who is also the grant’s principal investigator. “Equally important is the awareness we are doing in underserved communities as we seek to reduce the burden of cancer in the region.”
The cancer center is conducting more than 200 clinical trials active at any time, including the region’s only Phase 1 trials. Hundreds of scientists and employees are involved in this cutting-edge research. Numerous trials test new therapies or innovative anticancer approaches developed by UC Davis laboratories and are only available at the UC Davis Comprehensive Cancer Center.
“The renewal of the NCI Award is a remarkable achievement and means that UC Davis will continue to advance its groundbreaking work, collaborating among clinicians, researchers, educators, staff and, of course, our clinical trial participants, as we share a common goal; beat cancer, ”said Vice Chancellor of Research Prasant Mohapatra.
The award demonstrates high-quality collaboration between dozens of disciplines across multiple departments at UC Davis.
“At UC Davis School of Medicine, we encourage team science and believe that innovation is inspired by diversity of thought. The NCI Prize will help expand our transdisciplinary collaborations to identify new cancer treatments, ”said Dean Allison Brashear. “This year, the School of Medicine achieved a record level of research funding with $ 368 million in awards. Our collective efforts not only improve the lives of our patients and the community, but also have an impact in the whole world.”
UC Davis Comprehensive Cancer Center first received NCI designation as an anticancer center in 2002 with “global” status awarded in 2012. It has since expanded its innovative cancer control programs to include cancer technology. robotic surgery and theranostics; using the same imaging technology that detects cancer killing tumors with precision. In 2019, the Cancer Center inaugurated its EXPLORER Molecular Imaging Center, the world’s first combined clinical total body research and PET center.
The cancer center is also one of the few in the country to partner with veterinary science, namely the country’s No.1 veterinary school, UC Davis School of Veterinary Medicine, to run a new program. comparative oncology that combines the human and the companion. animal oncology. Research is seen as crucial to advancing understanding of tumor biology, accelerating the development of therapies, and giving hope to people and their pets affected by cancer.
Among its many other strengths, the cancer center is distinguished by its world-class research in cancer biology and DNA repair, immunotherapy, precision oncology and its strong programs for the development of new cancer drugs.
He has more and more programs in supportive care for cancer patients. As the only clinic in the region to manage the long-term effects of treatment on childhood cancer survivors, the cancer center is also a leader in pediatric oncology. He recently launched the region’s only adolescent and young adult oncology program.
Recognized by US News & World Report as one of the nation’s top cancer care hospitals, the UC Davis Comprehensive Cancer Center treats over 20 types of cancer, including the most aggressive tumors such as cancer. pancreas. A recently awarded $ 4 million Pancreatic Cancer Collective grant to the cancer center will fund an early stage clinical trial to test the delivery of radioactive isotopes directly into pancreatic cancer cells.
UC Davis Comprehensive Cancer Center